Standardized neoadjuvant chemotherapy for gastric cancer
LI Zi-yu
MIAO Ru-lin
JI Jia-fu
Abstract：Gastric cancer is one of the most common malignant tumors in China and the advanced cancer accounts the majority. Several studies proved that neoadjuvant chemotherapy could shrink the tumor and improve the resection rate resulting in better prognosis. However, there is still lack of standardization in the neoadjuvant chemotherapy for gastric cancer. Standardized treatment requires precise pretreatment evaluation for the histological type and clinical stage of the tumor. Together with the personal factors of the patients, personalized strategy should be considered. During treatment, active monitoring should be applied to determine the course of neoadjuvant chemotherapy and strategy of postoperative chemotherapy. Currently, there are still lots of questions need to be answered to standardize the neoadjuvant chemotherapy of gastric cancer, but it should believe that with the secrets uncovered by large clinical trials, neoadjuvant chemotherapy would play a more and more important role in the multimodality treatment of gastric cancer.
Keywords：gastric canerstandardizationneoadjuvant chemotherapy
Publication Date：2014-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：3( 627-629 )